查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1535663

胰臟癌诊断市场- 副产品（仪器、消耗品）、测试类型（影像[CT、MRI、超音波、PET]、活检、血液检查[肝功能、肿瘤标记]）、癌症类型（外分泌、内分泌）、末端-使用-全球预测（2024 - 2032）

Pancreatic Cancer Diagnostic Market - By Product (Instruments, Consumables), Test Type (Imaging [CT, MRI, Ultrasound, PET], Biopsy, Blood Test [Liver Function, Tumor Marker]), Cancer Type (Exocrine, Endocrine), End-use- Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 298 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在胰臟癌盛行率上升的推动下，全球胰臟癌诊断市场在 2024 年至 2032 年期间复合年增长率将达到 9.1%。据世界卫生组织称，到 2030 年，胰腺癌病例预计将增加 55%。基于生物标记的测试、液体活检以及内视镜超音波和 MRI 等成像技术等创新提高了早期检出率，考虑到胰腺癌的侵袭性，这一点至关重要。这些进步提高了诊断准确性并实现个人化治疗计划，增加了对复杂工具的需求。

癌症研究资金和投资的增加也推动了市场的成长。政府和私人组织正在大力投资开发和改进诊断方法。例如，美国国家癌症研究所将在 2023 年拨款超过 60 亿美元用于癌症研究。此外，不断增长的老年人口更容易患胰臟癌，这凸显了对先进诊断解决方案的需求。

整个胰臟癌诊断产业根据产品、测试类型、癌症类型、最终用途和地区进行分类。

活检部分预计在 2032 年之前获得显着的发展，这主要是因为它们在确认疾病的存在和阶段方面发挥关键作用。活检测试，特别是细针抽吸和空心针活检，为准确诊断提供了必要的明确的组织病理学证据。随着影像引导活检技术的进步，这些手术的精确度和安全性显着提高。此外，对个人化医疗的日益重视需要对肿瘤组织进行详细的遗传和分子分析，而这些分析只能透过活检样本获得。

由于专注于开创性研发计划，预计到 2032 年，癌症研究机构部门将占据显着的市场份额。这些研究所处于发现新型生物标记、完善诊断技术以及开发提高早期检测和诊断准确性的尖端技术的前沿。透过进行广泛的临床试验和转化研究，癌症研究机构促进了创新诊断工具的引入。此外，他们与生物技术公司和医疗保健提供者的合作加速了这些先进诊断技术在临床环境中的采用。这些机构的研究成果不断涌入，不仅推动了技术进步，而且还创造了诊断实践持续改进和适应的环境。

在医疗保健支出增加、癌症诊断意识提高以及医疗技术进步的推动下，到 2032 年，亚太地区胰臟癌诊断产业将录得强劲的复合年增长率。由于人口老化和生活方式的改变，胰臟癌的发生率较高，这促使对有效诊断解决方案的需求更大。此外，旨在改善癌症护理基础设施的政府倡议以及能够获得更好医疗服务的新兴中产阶级的出现也有助于市场扩张。充满活力的製药和生技产业，加上对研发的高度重视，将进一步塑造区域市场动态。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 胰臟癌盛行率增加
      • 诊断技术的进步
      • 全球医疗保健支出不断增长
      • 人们对早期癌症检测的认识不断提高
    • 产业陷阱与挑战
      • 严格的监管场景
      • 诊断测试成本高
  • 成长潜力分析
  • 报销场景
  • 监管环境
  • 技术景观
    • 核心技术
    • 邻近技术
  • 2023 年定价分析
    • 按地区
    • 按关键人物
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 仪器仪表
  • 耗材

第 6 章：市场估计与预测：按测试类型，2021 - 2032

  • 主要趋势
  • 影像学检查
    • CT扫描
    • 核磁共振成像
    • 超音波
    • 宠物
    • 其他影像学检查
  • 活检
  • 验血
    • 肝功能检查
    • 肿瘤标记
    • 其他血液检查
  • 其他测试类型

第 7 章：市场估计与预测：按癌症类型，2021 - 2032 年

  • 主要趋势
  • 外分泌
    • 腺癌
    • 鳞状细胞癌
    • 腺鳞癌
    • 胶体癌
  • 内分泌

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 诊断实验室
  • 诊断影像中心
  • 癌症研究机构

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ASURAGEN, INC.
  • Becton, Dickinson and Company
  • BioMarker Strategies
  • Canon Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Hitachi, Ltd.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Myriad Genetics, Inc.
  • Prestige Biopharma Limited (PBP)
  • QIAGEN N.V.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: 9826

The global pancreatic cancer diagnostic market will record 9.1% CAGR over 2024-2032, driven by the rising prevalence of pancreatic cancer. According to the World Health Organization, pancreatic cancer cases are expected to rise by 55% by 2030. Sedentary lifestyles and high-fat, low-fiber diets have contributed to this increase in cases, pushing the demand for advanced diagnostic tools. Innovations such as biomarker-based tests, liquid biopsies, and imaging techniques like endoscopic ultrasound and MRI have improved early detection rates, which is crucial given the aggressive nature of pancreatic cancer. These advancements enhance diagnostic accuracy and enable personalized treatment plans, increasing the demand for sophisticated tools.

Increased funding and investment in cancer research is also driving market growth. Governments and private organizations are investing heavily in developing and improving diagnostic methods. For instance, the National Cancer Institute allocated over $6 billion for cancer research in 2023. Public awareness campaigns about early diagnosis and regular screenings have led to higher patient participation in diagnostic procedures. Additionally, the growing elderly population, more susceptible to pancreatic cancer, underscores the need for advanced diagnostic solutions.

The overall pancreatic cancer diagnostic industry is classified based on product, test type, cancer type, end use, and region.

The biopsy segment is poised for significant traction through 2032, primarily due to their critical role in confirming the presence and stage of the disease. Biopsy tests, particularly fine-needle aspiration and core needle biopsies, provide definitive histopathological evidence necessary for accurate diagnosis. With advancements in imaging-guided biopsy techniques, the precision and safety of these procedures have significantly improved. Additionally, the growing emphasis on personalized medicine necessitates detailed genetic and molecular profiling of tumor tissues, which can only be obtained through biopsy samples.

The cancer research institutes segment is anticipated to hold a notable market share by 2032, due to focus on pioneering R&D initiatives. These institutes are at the forefront of discovering novel biomarkers, refining diagnostic techniques, and developing cutting-edge technologies that enhance early detection and diagnosis accuracy. By conducting extensive clinical trials and translational research, cancer research institutes facilitate the introduction of innovative diagnostic tools. Moreover, their collaborations with biotechnology firms and healthcare providers accelerate the adoption of these advanced diagnostics in clinical settings. The continual influx of research findings from these institutes not only drives technological advancements but also fosters an environment of ongoing improvement and adaptation in diagnostic practices.

Asia Pacific pancreatic cancer diagnostic industry will record a strong CAGR through 2032, driven by increasing healthcare expenditures, rising awareness of cancer diagnostics, and advancements in medical technology. There is a higher incidence rate of pancreatic cancer due to aging populations and lifestyle changes, prompting greater demand for effective diagnostic solutions. Additionally, government initiatives aimed at improving cancer care infrastructure and the presence of a burgeoning middle class with access to better healthcare services contribute to market expansion. The dynamic pharmaceutical and biotech sectors, coupled with a strong emphasis on R&D will further shape the regional market dynamics.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of pancreatic cancer
      • 3.2.1.2 Advancements in diagnostic technologies
      • 3.2.1.3 Growing healthcare expenditure globally
      • 3.2.1.4 Rising awareness regarding early cancer detection
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory scenarios
      • 3.2.2.2 High cost of diagnostic tests
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
  • 3.6 Technological landscape
    • 3.6.1 Core technologies
    • 3.6.2 Adjacent technologies
  • 3.7 Pricing analysis, 2023
    • 3.7.1 By region
    • 3.7.2 By key player
  • 3.8 Future market trends
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
  • 5.3 Consumables

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Imaging test
    • 6.2.1 CT scan
    • 6.2.2 MRI
    • 6.2.3 Ultrasound
    • 6.2.4 PET
    • 6.2.5 Other imaging tests
  • 6.3 Biopsy
  • 6.4 Blood test
    • 6.4.1 Liver function tests
    • 6.4.2 Tumor markers
    • 6.4.3 Other blood tests
  • 6.5 Other test types

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Exocrine
    • 7.2.1 Adenocarcinoma
    • 7.2.2 Squamous cell carcinoma
    • 7.2.3 Adenosquamous carcinoma
    • 7.2.4 Colloid carcinoma
  • 7.3 Endocrine

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Diagnostic laboratories
  • 8.4 Diagnostic imaging centers
  • 8.5 Cancer research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Agilent Technologies, Inc.
  • 10.3 ASURAGEN, INC.
  • 10.4 Becton, Dickinson and Company
  • 10.5 BioMarker Strategies
  • 10.6 Canon Inc.
  • 10.7 Danaher Corporation
  • 10.8 F. Hoffmann-La Roche Ltd.
  • 10.9 GE HealthCare Technologies Inc.
  • 10.10 Hitachi, Ltd.
  • 10.11 Illumina, Inc.
  • 10.12 Koninklijke Philips N.V.
  • 10.13 Myriad Genetics, Inc.
  • 10.14 Prestige Biopharma Limited (PBP)
  • 10.15 QIAGEN N.V.
  • 10.16 Siemens Healthineers AG
  • 10.17 Sysmex Corporation
  • 10.18 Thermo Fisher Scientific Inc.